Research utilizing the ID8 Trp53-/- murine ovarian cancer model has demonstrated that a novel dual EHMT2/EZH2 inhibitor, HKMTI-1–005, significantly upregulates chemokine expression, including cxcl9, cxcl10, and ccl5, following IFNγ stimulation in vitro. This evidence concerns the gene EZH2 and ovarian carcinoma.